1Sever PS,Dahl of B,Poulter NR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration,in the angi o-scandinavian carsdic outcomes trial-lipid-lowering arm (ASCOT-LLA):a multicentre randomized controlled trial[J].Lancet,2003,361:1149-2258.
2Mellors A,Tappel A L.The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol[J].J Biol Chern,1966,241:4353-4356.
3Moride Y,Hegele RA,Langer A,et al.Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events:resolved and unresolved issue[J].Can J Cardiol,2008,24 (4):293-300.
4Vasa M,Fichtlscheres S.Increaes in circulating endothelial progenitor cells by statin therapy in patients with stable cororary artery disease[J].Circulation,2001,103 (9):2885-2890.
5Amorose G,Van Veldhuisen DJ,Tio RA,et al.Pathophysiology of vascular endothelium and circulation platelets:Implications for coronary revasculavisation and treatmet[J].Int J Cardiol,2001,79(223):265-275.
6Wassmann S,Lau fs U,Baumer AT.Inhibition of gerannylgeranylation reduces angiotensin Ⅱ mediated free radical production in vascular smooth cells:involvment of angiotensin AT I recepfor expression and Racl GTP ase[J].Mol Pharmcol,2001,59(3):646-654.
8Walker JL,Smith GH,Gaston MS,et al.Spontaneous compartment syndrome in association with simvastatin-induced myositis[J].Emerg Med J,2008,25 (5):305-306.
9Crane FL.Biochehaeal functions of coenzyme Q10.J AM Coll Nutr,2001,20(6):591-598.
10Young XY,Jabbour S,Goldberg R,et al.Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease[J].Am J Cardiol,2003,92:1379 -1383.
4Ueda K,Takahashi M,Yamada T,et al.Evaluation of changes in hepatic energy metabolism during exercise by ketone body ratio in humans[J].J Cardiol,1997,29:95-102.
5Karlsson J,Lin L,Sylven C,et al.Muscle ubiquinone in healthy physically active males[J].Mol Cell Biochem,1996,156:169-172.
6Ylikoski T,Piirainen J,Hanninen O,et al.The effect of coenzyme Q10 on the exercise performance of crosscountry skiers[J].Molec Aspects Med,1997,18:s283-290.
7Zhou S,Zhang Y,Davie A,et al.Muscle and plasma coenzyme Q(10) concentration,aerobic power and exercise economy of healthy men in response to four weeks of supplementation[J].J Sports Med Phys Fitness,2005,45(3):337-346.
8Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the natioual cholesterol education program adult treatment panel III. Guidelines [ J ]. J Am Coll Cardiol, 2004, 144(3) :720-732.
9Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs[J]. Toxicol Lett, 2002,128(1-3) :159-168.
10Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis[J]. N Engl J Med, 2002, 346(7) : 539-540.
6Staffa JA,Chang J,Green L.Cerivastatin and reports of fatal rhabdomyolysis[J].Nengl J Med,2002,346(7):539-540.
7Venero CV,Thompson PD.Managing statin myopathy[J].Endocrinol Metab Clin North Am,2009,38(1):121-136.
8Baer AN,Wortmann RL.Myotoxicity associated with Lipilowering drugs[J].Curr Opin Rheumatol,2007,19(1):67-73.
9Kashani A,PhillipsCO,Foody JM.Risks assciated with statin therapy:a systematic overview of randomized clinical trials[J].Circulation,2006,114(25):2788-2797.
10Kaspera R,Naraharisetti SB,Tamraz B,et al.Cerivastatin in vitro metabolism by CYP2C8 vayiants found in patients experiencing rhabdomyolysis[J].Pharmacogenet Genomics,2010,20(10):619-629.
